Erenumab
Erenumab is a monoclonal antibody medication used for the preventive treatment of migraine in adults. It works by blocking calcitonin gene-related peptide (CGRP) receptors, which are involved in migraine pain signaling. Administered as a monthly subcutaneous injection, it is prescribed for patients with episodic or chronic migraine.
Erenumab is a CGRP receptor antagonist monoclonal antibody injection used to prevent migraines in adults.
Key facts at a glance
- ATC
- N02CD01
- RxNorm
- 2045613
- Generic
- Erenumab
- Class
- atc-n02
- Brands
- Aimovig
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 70mg or 140mg once monthly
- Maximum
- consult physician
- Frequency
- once monthly
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 70mg once monthly
- Maximum
- consult physician
- Frequency
- once monthly
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 70mg or 140mg once monthly
- Maximum
- consult physician
- Frequency
- once monthly
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
10 groupspregnancy
first trimesteravoid if possible
use only if benefits outweigh potential risks to fetus
regular prenatal monitoring recommended
pregnancy
second trimesteravoid if possible
continue only if benefits outweigh potential risks
regular prenatal monitoring recommended
pregnancy
third trimesteravoid if possible
discontinue prior to delivery if possible
regular prenatal monitoring
lactation
breastfeedingno adjustment needed
use with caution; limited data on breast milk transfer
monitor infant for adverse effects
pediatric_age
under 18 yearsnot recommended
not approved for use in patients under 18 years of age
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
geriatric
65 years and olderno adjustment needed
can be used in older adults; monitor for comorbidities
routine monitoring for blood pressure and cardiovascular status
Use with caution and monitor for adverse effects.
renal_impairment
mild moderateno adjustment needed
no dose adjustment required for mild to moderate renal impairment
routine monitoring
renal_impairment
severeno adjustment needed
use with caution; limited clinical data available
close monitoring
Use with caution and monitor for adverse effects.
hepatic_impairment
mild moderateno adjustment needed
no dose adjustment required for mild to moderate hepatic impairment
routine monitoring
hepatic_impairment
severeno adjustment needed
use with caution; limited clinical data available
close monitoring
Use with caution and monitor for adverse effects.
Statistics and clinical data
Drug class
Pharmacological classification of Erenumab
FDA approval year
FDA regulatory approval information
Mechanism of action
Pharmacological mechanism of action
Primary indication
Therapeutic indication
Preventive treatment of episodic and chronic migraine in adults who experience at least 4 migraine days per month. It is not used to treat acute migraine attacks.
Erenumab is a fully human monoclonal antibody that selectively binds to and blocks the calcitonin gene-related peptide (CGRP) receptor. By preventing CGRP from binding to its receptor, it reduces the neurogenic inflammation and pain signaling associated with migraines.
Administered as a monthly subcutaneous injection (70mg or 140mg). Common side effects may include injection site reactions, constipation, and hypertension. Patients should be monitored for serious allergic reactions. Not recommended during pregnancy unless clearly needed.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy